3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
22
Carcinoma, Transitional Cell
20
Ureteral Neoplasms
7
Urologic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasm Metastasis
3
Urogenital Neoplasms
2
Urethral Neoplasms
2
Muscle Invasive Bladder Urothelial Carcinoma
2
Metastatic Urothelial Cancer
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Advanced Bladder Cancer
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urachal adenocarcinoma
1
Triple Negative Breast Neoplasms
1
Salivary Gland Neoplasms
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Peripheral Nervous System Diseases
1
Penile Squamous Cell Carcinoma (PSCC)
1
Penile Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Interventions
pembrolizumab
4
Nivolumab
4
fludarabine
3
aldesleukin
3
Ipilimumab
3
Cyclophosphamide
3
vedolizumab
2
enfortumab vedotin
2
darolutamide
2
cabozantinib
2
atezolizumab
2
Specimen Handling
2
Riluzole
2
Prednisone
2
Magnetic Resonance Spectroscopy
2
LDP-02
2
Infliximab
2
Immunoglobulin G
2
Fecal Microbiota Transplantation
2
Disulfides
2
CTLA-4 Antigen
2
CT-P13
2
Biopsy
2
relatlimab
1
prednylidene
1
palbociclib
1
olaparib
1
gallium 68 PSMA-11
1
deltacortene
1
abiraterone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
enfortumab vedotin
×
1 year
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled
NCT06724159
2026-02-17
SOGUG-PRINCIS
Spanish Oncology Genito-Urinary Group
Recruiting
500 enrolled